HK1146054A1 - Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof - Google Patents

Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Info

Publication number
HK1146054A1
HK1146054A1 HK11100255.7A HK11100255A HK1146054A1 HK 1146054 A1 HK1146054 A1 HK 1146054A1 HK 11100255 A HK11100255 A HK 11100255A HK 1146054 A1 HK1146054 A1 HK 1146054A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
substituted
therapeutic use
bipyrrolidine carboxamides
bipyrrolidine
Prior art date
Application number
HK11100255.7A
Other languages
English (en)
Inventor
Werngard Czechtizky
Zhongli Gao
William J Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1146054A1 publication Critical patent/HK1146054A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK11100255.7A 2007-10-17 2011-01-12 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof HK1146054A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060107P 2007-10-17 2007-10-17
PCT/US2008/079760 WO2009052065A1 (fr) 2007-10-17 2008-10-14 Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique

Publications (1)

Publication Number Publication Date
HK1146054A1 true HK1146054A1 (en) 2011-05-13

Family

ID=40243633

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100255.7A HK1146054A1 (en) 2007-10-17 2011-01-12 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Country Status (26)

Country Link
US (1) US8618159B2 (fr)
EP (1) EP2212282B1 (fr)
JP (1) JP5255644B2 (fr)
KR (1) KR20100092441A (fr)
CN (1) CN101903339B (fr)
AT (1) ATE525350T1 (fr)
AU (1) AU2008312638B2 (fr)
BR (1) BRPI0818626A2 (fr)
CA (1) CA2702482C (fr)
CO (1) CO6190616A2 (fr)
CY (1) CY1112683T1 (fr)
DK (1) DK2212282T3 (fr)
ES (1) ES2374116T3 (fr)
HK (1) HK1146054A1 (fr)
HR (1) HRP20110953T1 (fr)
IL (1) IL205003A0 (fr)
MA (1) MA31855B1 (fr)
MX (1) MX2010004094A (fr)
MY (1) MY149650A (fr)
NZ (1) NZ584688A (fr)
PL (1) PL2212282T3 (fr)
PT (1) PT2212282E (fr)
RU (1) RU2477719C2 (fr)
SI (1) SI2212282T1 (fr)
WO (1) WO2009052065A1 (fr)
ZA (1) ZA201001946B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009052062A1 (fr) * 2007-10-17 2009-04-23 Sanofi-Aventis Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique
MX2010004003A (es) * 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
PL2215058T3 (pl) 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
EP2569304A1 (fr) * 2010-05-11 2013-03-20 Sanofi Bipyrrolidines n-hétéroaryl spirolactame substituées, procédé de préparation et usage thérapeutique associés
EP2569296A1 (fr) * 2010-05-11 2013-03-20 Sanofi Bipyrrolidines n-phényl spirolactame substituées, procédé de préparation et usage thérapeutique associés
WO2011143150A1 (fr) 2010-05-11 2011-11-17 Sanofi Spirolactames et amides de phénylcycloalkylpyrrolidine (pipéridine) substitués, leur préparation et leur utilisation thérapeutique
TW201206444A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
TW201206889A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
WO2011143161A1 (fr) * 2010-05-11 2011-11-17 Sanofi Dérivés de n-hétérocycloalkyl-bipyrrolidinylphénylamide substitués, préparation et utilisation thérapeutique de ceux-ci
AR081383A1 (es) * 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
US9309212B2 (en) 2011-05-24 2016-04-12 The Wistar Institute Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
WO2014134391A1 (fr) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2004037257A1 (fr) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT1861360E (pt) 2005-03-17 2010-01-28 Lilly Co Eli Derivados de pirrolidina como antagonistas de receptores h3 de histamina
CA2602234C (fr) * 2005-04-01 2014-01-14 Eli Lilly And Company Agents agissant sur le recepteur h3 de l'histamine, leur preparation et leurs utilisations therapeutiques
EP1904442B1 (fr) * 2005-07-01 2011-09-07 Eli Lilly And Company Agents recepteurs de l'histamine h3, preparation et utilisations therapeutiques
CA2627234A1 (fr) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Composes comprenant un lactame ou un groupement derive de lactame, procedes de fabrication de ceux-ci, et leurs utilisations
PL2215058T3 (pl) 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
WO2009052062A1 (fr) * 2007-10-17 2009-04-23 Sanofi-Aventis Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique
MX2010004003A (es) * 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.

Also Published As

Publication number Publication date
ATE525350T1 (de) 2011-10-15
HRP20110953T1 (hr) 2012-01-31
CN101903339B (zh) 2012-06-27
EP2212282B1 (fr) 2011-09-21
WO2009052065A1 (fr) 2009-04-23
CA2702482C (fr) 2012-11-27
BRPI0818626A2 (pt) 2015-09-29
SI2212282T1 (sl) 2012-01-31
CY1112683T1 (el) 2016-02-10
MA31855B1 (fr) 2010-11-01
MX2010004094A (es) 2010-04-30
PL2212282T3 (pl) 2012-02-29
RU2010119560A (ru) 2011-11-27
US8618159B2 (en) 2013-12-31
AU2008312638B2 (en) 2013-05-16
ES2374116T3 (es) 2012-02-13
RU2477719C2 (ru) 2013-03-20
PT2212282E (pt) 2012-01-09
EP2212282A1 (fr) 2010-08-04
JP2011500696A (ja) 2011-01-06
JP5255644B2 (ja) 2013-08-07
CA2702482A1 (fr) 2009-04-23
US20100173897A1 (en) 2010-07-08
IL205003A0 (en) 2010-11-30
ZA201001946B (en) 2010-10-27
CO6190616A2 (es) 2010-08-19
AU2008312638A1 (en) 2009-04-23
CN101903339A (zh) 2010-12-01
NZ584688A (en) 2011-12-22
KR20100092441A (ko) 2010-08-20
MY149650A (en) 2013-09-30
DK2212282T3 (da) 2012-01-23

Similar Documents

Publication Publication Date Title
HK1146053A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HK1146054A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HK1146056A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
TN2011000233A1 (en) Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
TN2010000373A1 (en) The present invention provides oxadiazoanthracene

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161014